Q-omics provides the consensus-scored CA1 profile across patient tissues and cancer cell-line models. CA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CA1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, CA1 RNA expression shows 12,053 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight DLBC, COAD, and LUAD as cancer lineages where CA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA1 survival associations across molecular data types. CA1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA1 RNA expression–survival associations across cancer types. High CA1 expression shows unfavorable associations in DLBC, KICH, LGG, CESC and UCEC, but favorable associations in LUAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for CA1 RNA expression.
This table summarizes CA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA1 shows lower tumor expression in COAD, LUSC, LUAD, READ and BRCA and higher tumor expression in KIRC. The COAD box plot shows higher CA1 RNA expression in normal versus tumor tissue (log2 FC = −7.670, t-test p < 0.001).
This table shows molecular features associated with CA1 in patient tissues and cancer cell lines. In patient samples, CA1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
